Greg Biesecker

Title: Greg Biesecker: Innovator in Nucleic Acid Ligands

Introduction

Greg Biesecker is a notable inventor based in Boulder, CO (US). He has made significant contributions to the field of nucleic acid ligands, holding a total of 3 patents. His work focuses on innovative methods that enhance the specificity and efficacy of biological interactions.

Latest Patents

One of his latest patents is titled "Systematic evolution of ligands by exponential enrichment: blended SELEX." This method describes the generation of blended nucleic acid ligands that incorporate non-nucleic acid functional units. Specifically, it details a SELEX-identified RNA ligand targeting the integrin gpIIbIIIa, which is conjugated to the peptide Gly-Arg-Gly-Asp-Thr-Pro (SEQ ID NO:1). This blended RNA ligand demonstrates high specificity in inhibiting the biological activity of gpIIbIIIa. Additionally, the patent describes a single-stranded DNA ligand to elastase, coupled with N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (SEQ ID NO:2). This elastase blended nucleic acid ligand also effectively inhibits the biological activity of elastase.

Career Highlights

Throughout his career, Greg Biesecker has worked with prominent companies in the pharmaceutical industry, including Nexstar Pharmaceuticals, Inc. and Gilead Sciences, Inc. His experience in these organizations has contributed to his expertise in the development of innovative ligands.

Collaborations

Greg has collaborated with esteemed colleagues such as Sumedha D Jayasena and Larry M Gold. These partnerships have further enriched his research and development efforts in the field of nucleic acid ligands.

Conclusion

Greg Biesecker is a distinguished inventor whose work in nucleic acid ligands has led to significant advancements in biological specificity and efficacy. His contributions continue to impact the field positively.